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The  androgen-regulated  20-kDa protein gene con- 
sists of four exons that code for a major secretory 
protein of rat  ventral prostate. Analysis of its potential 
cis-acting transcriptional  regulatory elements re- 
vealed that a large  intron 1 region (In-1)  had  stronger 
androgen response element (ARE) activity  than did the 
5’-flanking DNA. In cotransfected CV1 cells, In-1  and 
its most active subfragment In-lc functioned as AREs 
but not  glucocorticoid response elements (GRE). 
Nevertheless several ARE/GRE-like partial palin- 
dromic sequences are present  in In-lc, and it bound 
both androgen receptors  and glucocorticoid receptors 
in mobility shift assays. A cluster of three ARE/GRE- 
like sequences contained within a 39-base pair se- 
quence of In- IC had  both ARE and GRE activities when 
analyzed as an isolated oligonucleotide, suggesting that 
other elements within In-lc determined its ARE spec- 
ificity. In addition to ARE/GRE-like sequences, In-lc 
contains putative response elements for  the  transcrip- 
tion factors AP1, CREB, AP2, OCT-1, C/EBP, and a 
number of inverted  and  direct repeats. The ARE spec- 
ificity of In-lc observed in CV1 cells was diminished 
in PC3 and HeLa cells transiently cotransfected with 
an androgen receptor  or glucocorticoid receptor 
expression vector together with  an In-lc reporter vec- 
tor; however, the ARE activity of In-lc was greater 
than  its GRE activity  in these cell lines. Interestingly, 
a 131-base  pair subfragment of In-lc retained ARE 
specificity in  all  three cell lines. 
Regulatory effects of steroid hormone receptors on gene 
transcription are initiated by their interactions with nucleo- 
tide sequences referred to  as hormone response elements (1- 
3). These  elements are recognized  by the receptor DNA bind- 
ing domain, a  cysteine-rich region containing two zinc fingers 
*This work was supported by Grants HD04466, P30-HD18968 
(DNA and Tissue Culture Cores), and T32-HDQ7315 from The 
National  Institute of Child Health  and  Human  Development  Center 
for Population  Research,  T32-DK07129 from the Medical Research 
Council of Canada,  and by The  Andrew W. Mellon  Foundation.  The 
costs of publication of this article were defrayed in part by the 
payment of page charges. This article must therefore be hereby 
marked “aduertisement” in  accordance  with 18 U.S.C.  Section 1734 
solely to  indicate this fact. 
The nucleotide sequence(s) reported in  thispaper has been submitted 
to  the  GenBankTM/EMBL  Data  Bank  with accession numbeds) 
L12454. 
§ To whom  correspondence  should be addressed  Laboratories for 
Reproductive  Biology,  University of North Carolina, CB  7500, Mac- 
nider Bldg., Chapel Hill, NC 27599-7500. Tel.: 919-966-5159; Fax: 
919-966-2203. 
(4). The subfamily of nuclear receptors, which includes an- 
drogen (AR),’ glucocorticoid (GR), progesterone, and miner- 
alocorticoid receptors, contains a high degree of sequence 
similarity  within the DNA binding domains of the receptors 
(5). This sequence homology is reflected in their common 
interactions with a  similar class of response elements  consist- 
ing of 15 bp  partial palindromic sequences (3,6-12).  Studies 
on the androgen-regulated prostatein C3 subunit gene iden- 
tified a potent androgen response element  (ARE) 
AGTACGn,TGTTCT (9,10,13) within the first intron which 
also functions as a glucocorticoid response element  (GRE) in 
transient cotransfection  assays (14). Several weaker elements 
were identified within the C3 first intron and 5”flanking 
regions, and these  too displayed both ARE and GRE activities 
(10, 14). This set of simple response elements provides a 
plausible basis for the overlapping androgen and glucocorti- 
coid effects on gene expression which have been demonstrated 
in  rat ventral  prostate. However, the predominant androgen 
dependence of gene expression in rat  prostate suggests that 
there exist more specific AREs that respond selectively to 
androgen. 
Thus far an AR-specific single 15-bp palindromic sequence 
has  not been identified, but receptor specificity may be deter- 
mined by more complex response elements. Recent  studies on 
the AR, GR, progesterone receptor subfamily have shown that 
transactivation can be mediated by complex elements that 
include multiple simple steroid response elements (15-bp par- 
tial palindromes or half-sites)  together with recognition se- 
quences for other  transcription factors.  A response element 
of this type could provide a framework for modulation of 
receptor transactivation by other factors  through  both  pro- 
tein-protein and protein-DNA  interactions (3, 12, 15-21). 
Herein we report on a complex element that responds 
selectively to  the androgen receptor. The complex androgen 
response element is located in the first intron of the androgen- 
regulated 20-kDa protein gene that codes for one of the major 
secretory proteins of rat ventral prostate  and lacrimal gland 
(22-24). This intron element conferred androgen but not 
glucocorticoid receptor responsiveness to a heterologous pro- 
moter in transient cotransfection  experiments utilizing mon- 
key kidney CV1 cells. In  the  human  prostate cancer cell line 
PC3  and  in HeLa cells, both AR and GR transactivation was 
The  abbreviations used are: AR,  androgen  receptor; GR, gluco- 
corticoid  receptor;  bp,  base pair(s); ARE,  androgen  response  element; 
GRE,  glucocorticoid  response element; PCR,  polymerase  chain reac- 
phenicol acetyltransferase; DBD, DNA binding domain; C/EBP, 
tion; PIPES, 1,4-piperazinediethanesulfonic acid;  CAT, chloram- 
CCAAT and  enhancer core binding  protein;  CREB,  cyclic-adenosine 
monophosphate  response  element  binding  protein. 
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FIG. 1. Nucleotide sequence of the rat 20-kDa protein gene. Panel A ,  schematic diagram of the 20-kDa protein gene and its 
sequencing strategy. The sequence GATAAAA is the putative TATA box. Cross-hatched bars are exons. Open bars are 5'-flanking, introns 1, 
2, 3, and 3'-flanking regions. Residue numbers  are indicated relative to  the predicted mRNA start site. The restriction enzyme sites shown 
were used in sequencing: R, EcoRI; Hi, HinfI; A, AluI; H,  HincII. The sequence between nucleotides 3001 and 5399 was analyzed in 
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FIG. 2. Primer extension  analysis of the transcription start 
site of the PO-kDa protein gene. Lanes 1-4, sequencing  ladders of 
M13mp19 using the 17-mer  sequencing  primer -20 in the order of G, 
A, C, T. Lanes 5-7, the products of extension  using 1.0,  0.1, and 0.01 
pg  of rat ventral prostate poly(A) RNA as template. The arrow 
indicates the position of the longest DNA product which corresponds 
to a  G residue of M13mp19, 372 nucleotides from the 5’ start point 
of the 17-mer sequencing primer -20. This located the mRNA tran- 
scription start  site  at  an A residue of the genomic DNA sequence 
shown in Fig. 1. 
observed; however, the response to  AR remained greater than 
GR. 
MATERIALS AND  METHODS 
Genomic  Clones and DNA Sequencing-EcoRI and  HaeIII  partially 
digested rat genomic DNA libraries constructed in X Charon 4A were 
provided by T. Sargent, R. Wallace, and J. Bonner (California Insti- 
tute of Technology). Libraries were screened for the 20-kDa gene 
using two EcoRI cDNA fragments (nucleotides 237-352 and 353-809) 
as probes (22, 25). The DNA fragments were labeled with [a-’*P] 
dCTP by the multiprime DNA labeling system (Amersham Corp.). 
Genomic clones were digested with EcoRI and subjected to  Southern 
blot  analysis  using the cDNA probes  described above. 
EcoRI genomic DNA fragments hybridizing to cDNA  probes were 
cloned into M13mp19 or pGEM3zf(+) at  the EcoRI site. Subfrag- 
ments generated by restriction with different enzymes were blunt 
ended using T4 DNA polymerase and cloned into M13mp19 or 
pGEM3zf(+) a t  the SmaI site. Sequencing in M13mp19 was per- 
formed by the standard dideoxy chain termination method (26). 
Sequencing in pGEM3zf(+) was performed  using  a  series of synthetic 
oligonucleotide primers and Sequenase  according to  the  manufactur- 
er’s directions (U. S. Biochemical Corp.). 
tion  (PCR), purified by agarosi gel electrophoresis, and cloned into 
pGEMBzf(+) for sequencing. Single-stranded DNA was synthesized 
by asymmetric PCR, purified by centrifugation in Centricon-30 or 
-100 (Amicon Division, W. R. Grace & Co.), and sequenced using 
Sequenase. 
Primer Extension Analysis-The 5’ start  site of mRNA transcrip- 
tion was determined by primer  extension  analysis as described pre- 
viously (27). Total RNA was isolated from Sprague-Dawley rat (250- 
350 g) ventral prostate using the acid guanidinium thiocyanate- 
phenol-chloroform method (28) and enriched for poly(A) RNA by 
oligo(dT)-cellulose  chromatography (25). The 5’ end  ”P-labeled oli- 
gonucleotide, 5’-CCCTCTGGAAAGAACATTGTAGAAGTCAG- 
AACAATCTTTCTACATTTGGTTTTAACC-3’ (nucleotides 3079- 
3021 in Fig. 1B) was incubated with decreasing amounts (1.0-0.01 
pg) of rat  ventral  prostate poly(A) RNA in 50% formamide, 0.4 M 
NaCl, 1 mM EDTA, and 40 mM PIPES,  pH 6.4, a t  85 “C for 10 min 
and placed a t  42.5 “C for 6 h. After ethanol precipitation, the oligo- 
nucleotide was extended with avian myeloblastosis virus reverse 
transcriptase  (Promega)  on  the 20-kDa mRNA. DNA products were 
subjected to electrophoresis on a 5% sequencing gel in parallel  with 
dideoxy sequencing  ladders of M13mp19 size markers. 
Plasmid Construction for Functional Analysis-DNA fragments or 
synthetic oligonucleotides were cloned into polylinker regions of the 
reporter vector ptkCAT 5‘ of the thymidine kinase promoter and 
chloramphenicol  acetyltransferase (CAT) gene or  the reporter vector 
pCAT 5’ of the CAT gene. ptkCAT  and pCAT were derived from 
pBLCAT2 and pBLCAT3 respectively, by removal of the 217-bp NdeI- 
Hind111 fragment containing a potential GRE sequence (29). All 
constructs were verified by double-stranded  sequencing  using oligo- 
nucleotide primers. Clone pFL-1  contains  the flanking region frag- 
primers 5’-GTAATTAAAGATAACTAAG-3’ (nucleotides -895 to 
ment FL-1,  nucleotides -895 to -38. FL-1 was prepared  using PCR 
-875) and 5’-CCTCCTACTAGCCAGACCTTCC-3’ (nucleotides 
-38 to -60) on the 1,426-bp EcoRI fragment. Fragment FL-1 was 
cloned into  the  T4 DNA polymerase-blunted BamHI site of ptkCAT. 
The flanking region containing nucleotides -901 to +8 was generated 
by cleaving the 1,426-bp EcoRI fragment with MboII and cloned into 
the  BamHI  site of pCAT by blunt end ligation. Clone pln-1  containing 
the  intron 1 fragment  In-1 was generated by restriction of the 2,559- 
bp EcoRI fragment  with BamHI  and cloning into  the  BamHI  site of 
ptkCAT by blunt  end ligation. 
Clone pIn-la  contains  the  intron 1 subfragment In-la (nucleotides 
1419-1779). The fragment was generated by restriction digestion of 
the fragment In-1 with HincII  then A L L  In-la was cloned into  the 
BamHI  site of ptkCAT by blunt  end ligation. Clones pIn-lb  and  pIn- 
IC were constructed similarly but contain the  intron 1 subfragments 
In-lb, nucleotides 2013-2290, and  In-lc, nucleotides 2549-2907, re- 
spectively. However, pIn-lc was first cloned in reverse orientation, 
cut with BamHI,  and reinserted in the correct  orientation to preserve 
the  BamHI sites.  Clone  pD1 contains  the larger subfragment (Dl)  of 
In-lc (nucleotides 2680-2907) cleaved by DdeI and cloned into  the 
SalI  site of ptkCAT by blunt  end ligation. Clone pD2 contains  the 
smaller  subfragment (D2) of In-lc, nucleotides 2549-2680, obtained 
by DdeI cleavage. Clone pN39 contains a 39-bp oligonucleotide of 
fragment In-lc, nucleotides 2684-2722. The oligonucleotide was pre- 
pared  with SalI  sites at  both ends  and cloned into  SalI  site of ptkCAT. 
pCMVrAR is  a pCMVl vector containing  full-length rat AR cDNA 
(10, 30). pCMVrGR was constructed by cloning the full-length rat 
GR (31) into pCMV1. 
Cell Culture, Transfection, and CATAssay-African green monkey 
kidney cells, CV1, were maintained at  37 “C under 5% CO, in Dul- 
becco’s modified Eagle’s medium-H  supplemented  with 5% fetal 
bovine serum. Human  prostate cancer cells, PC3, were maintained at  
“ .  I 
pGEMBZf(+) using synthetic oligonucleotide primers. Each sequence was determined on two different clones. The arrows indicate the 
sequencing directions. Sequences verifying the  continuity of adjacent EcoRI fragments  are indicated by arrows  with asterisk markers  and 
were obtained by the Sequenase method using 32P-labeled oligonucleotide primers  and genomic DNA in X phage as template. The broken- 
lined regions indicate the  PCR DNA products from rat genomic DNA using primers 5’-CTGACTTCTACAAATGTC””T’CCAGAGGG-3’ 
(nucleotides 3050-3079) and 5’-CCTCTAGTCCAGAGAGGAACACCAACTTAC-3’ (nucleotides 3395-3366) or 5”AGATAGGAGCTTCCT 
GCATCTGACGCTTCC-3’  (nucleotides 3925-3896). Both  fragments  contain  the  third EcoRI fragment (1,255 bp) which is in clone H8 (See 
“Results”). Sequences of the  end  portions of the  PCR DNA were determined  directly from asymmetric PCR products and by sequencing the 
smaller  double-stranded PCR DNA fragment cloned in  pGEM3zf(+).  Panel B, nucleotide  sequence of the 20-kDa protein gene in panel A. 
The mRNA start  site is  marked by * and numbered as +1. The  putative  TATA box is double-underlined and located centrally a t  -22. Coding 
regions are displayed with deduced amino acid sequences. The  first  intron region In-lc  containing  the complex ARE is underlined. EcoRI 
restriction sites  are boxed. 
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FIG. 3. Androgen-dependent en- 
hancer  activities  of  the  5’-flanking 
region  and  intron 1 fragment  In-1 
i n C V l  cells. Schematic diagram of the 
20-kDa protein gene and  the two frag- 
ments, FL-1 and In-1, cloned into the 
reporter vector ptkCAT for assay of an- 
drogen-dependent enhancer  activity (see 
“Materials and Methods” for construc- 
tion). CV1 cells were cotransfected with 
the androgen receptor expression vector 
pCMVrAR (1 pg) and (5 pg) of pFL- 
tkCAT containing the flanking region 
FL-1  or pIn-1-tkCAT  containing the  in- 
tron 1 fragment In-1. Lane I, recombi- 
nant reporter vector in the presence of 
50 nM R1881. Lane 2, recombinant re- 
porter vector plus pCMVrAR without 
R1881. Lane 3, the same as lane 2 but 
with 50 nM R1881. CAT activities were 
measured in CV1 cell extracts as de- 
scribed under “Materials and Methods.” 
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37 “C under 5% COz in Dulbecco’s  modified  Eagle’s medium and F- 
12 medium supplemented with 5% fetal bovine serum. Human  cer- 
vical carcinoma cells, HeLa, were maintained in Eagle’s minimal 
essential medium supplemented with 5% fetal bovine serum. One day 
before transfecting, cells were plated in 10-cm culture dishes a t  1.2 X 
lo6 cells/dish and grown in the same medium for 20 h when they 
were  70-80% confluent. (See the legend to Table 111 for modifications 
of the protocol in  experiments comparing regulation in CV1, PC3, 
and HeLa cells.)  Cells  were transfected with 1 pg  of receptor expres- 
sion vector DNA, pCMVrAR or pCMVrGR and 5 pg of reporter 
plasmid DNA using the CaPO, method as described previously (IO). 
Cells  were washed twice, placed in Dulbecco’s  modified  Eagle’s me- 
dium-H without phenol red and supplemented with 0.2% fetal bovine 
serum in the presence or absence of the indicated concentration of 
synthetic androgen, R1881 or synthetic glucocorticoid, dexametha- 
sone. After incubation for 20 h, the medium was replaced with or 
2 3 
1 2 3 
FIG. 4. Androgen-dependent en- 
hancer  activities of intron 1 
subfragments  in  CV1 cells. The dia- 
gram at  the top indicates relative loca- 
tions of In-l subfragments In-la,  In-lb, 
In-lc,  and arrows point to CAT assays 
with these fragments shown  below.  CV1 
cells were cotransfected with 5 pg  of 
recombinant reporter vector (tkCAT) 
containing In-la,  In-lb, or In-lc, and 1 
pg of the androgen receptor expression 
vector, pCMVrAR. Lane I ,  recombinant 
reporter vector (5 pg) in the presence of 
50 nM R1881. Lane 2, recombinant re- 
porter vector plus pCMVrAR (1 pg) 
without R1881. Lane 3, the same as lane 
2 but with 50 nM R1881. Data shown are 
representative of at least five experi- 
ments. CAT activities were measured in 
CV1  cell extracts  as described under 
“Materials  and Methods.” 
without hormone at  the same concentration. Cells were incubated for 
another 24 h, harvested in phosphate-buffered saline (0.15 M NaCl, 
0.01 M NazHP04, pH 7.2), and assayed for CAT activity  as described 
by Gorman et al. (32) except that  the cells were broken by freeze- 
thaw three times. Thin layer plates were  exposed on Kodak X-Omat 
AR film for 24-72  h. For quantitation, the radioactive spots were cut 
out from the plates and counted in a liquid scintillation counter. 
Stimulation of CAT activity was expressed as fold increase over 
background and was based on at  least five independent experiments. 
Mobility Shift DNA Binding Assay-DNA receptor binding was 
analyzed by  gel mobility shift using AR or GR DNA binding domain 
polypeptides and was performed as described previously (IO). Specific 
binding of receptor to DNA  was demonstrated using the protein A- 
purified IgG fraction of anti-AR antiserum (AR-52) or unpurified 
anti-GR antiserum (BuGR-2). 20-kDa protein gene fragments used 
in the mobility shift assay were inserts of ptkCAT vectors removed 
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FIG. 5. Comparison of androgen- 
and  glucocorticoid-dependent  en- 
hancer activities of intron 1 frag- 
ment   In-1   and   subf ragment   In- lc   in  
CV1 cells.  The diagram at  the top in- 
dicates In-1 and its subfragment In-lc 
with arrows pointing to  their respective 
CAT assays below. CV1 cells were co- 
transfected with pIn-1-tkCAT  or  pIn-lc- 
tkCAT (5 pg each) and pCMVrAR or 
pCMVrGR (1 pg each)  in  the presence 
or absence of increasing concentrations 
of R1881 or dexamethasone. Lune M, 
reporter vector containing the 5' most 
GRE of the mouse mammary tumor vi- 
rus long terminal repeat as a positive 
control. 
0 0 . )  m 
by restriction enzyme digestion to generate  B'-protruding ends  and 
purified by electroelution from polyacrylamide gels. The 5"protrud- 
ing ends were filled in with ["PIdCTP (Amersham Corp.) using 
Klenow fragment of DNA polymerase I  (Life  Technologies, Inc.). 
Ouerexpresswn of Recombinant Androgen and Glucocorticoid  Recep- 
tor-The rat  GR DNA binding domain (DBD)  (amino acid codons 
407-556) was excised from the expression vector pT7X556 by NdeI 
and ChI digestion and subcloned into the T7 RNA polymerase- 
dependent expression  vector pET16b (Novagen) at  the  same restric- 
tion sites. In addition to  non-GR residues present in T7X556, the 
resulting construct, pET16b-rGR-DBD,  contained  19  non-GR amino 
acids at the amino terminus contributed by pET16b including 10 
histidine residues which permit rapid purification using a nickel- 
containing affinity resin. 
A 510-bp DNA fragment corresponding to rat AR amino acid 
codons 495-665 encompassing the DNA binding  domain and hinge 
region of  AR was generated by PCR amplification  using oligonucle- 
otides that introduce BarnHI sites a t  either end of the amplified 
fragment. The  PCR product was digested with BamHI  and  inserted 
into  the expression vector pET16b. The resulting  expression  vector, 
pET16b-rAR-DBD, contained 19  non-rAR amino acids at   the amino 
terminus including 10 histidine  residues and 19 non-AR  amino-acids 
at  the carboxyl terminus including  a stop codon. 
BL21(DE3)pLysS,  a strain carrying  a stable  integrant of T7 RNA 
polymerase under the control of the lac UV5 promoter, was trans- 
formed with pET16b-rGR-DBD or pET16b-rAR-DBD, grown a t  
30 "C in LB medium containing carbenicillin and chloramphenicol, 
and induced at  midlogarithmic growth (AsW = 0.6-0.8)  by the addition 
of isopropyl-1-thio-P-D-galactopyranoside to 1 mM. After 2  h of 
induction, cells were collected by centrifugation,  resuspended in lysis 
buffer (20 mM Tris-HCI, pH 7.5,  0.5 M NaCI, 10% glycerol, and 
protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 pg/ml 
pepstatin, 2 pg/ml leupeptin, and 1 pg/ml aprotinin), and 5 mM 
imidazole, 0.04 ml/ml of culture)  and sonicated  on ice for three 10-s 
intervals. After 15 min on ice, sodium deoxycholate was added to 
0.05% and the suspension stirred for 30 min in an ice bath. The 
suspensions were centrifuged a t  40,000 X g for 30 min a t  4 "C. 
Supernatants were filtered through  a 0.45-pm filter and mixed with 
a nickel-containing affinity resin (His-BindTM, Novagen), 1 ml of 
resin/lO ml of supernatant, for 1 h a t  4 "C by inversion. Resin 
suspensions were packed into columns, washed sequentially  with 10 
ml of lysis buffer, 10 ml of lysis buffer containing 25 mM imidazole, 
and 10 ml of lysis buffer containing 50 mM imidazole. Receptor 
proteins rGR-DBD or rAR-DBD were eluted  with  5 ml of lysis buffer 
containing 200 mM imidazole. Protein fractions were dialyzed against 
TEGDZw (50 mM Tris-HCI, pH 7.5, 1 mM EDTA, 10% glycerol, 1 
mM dithiothreitol, 50 p~ ZnSO,, and 50 mM NaCI) for 4  h a t  4  "C, 
aliquoted, frozen in liquid N2, and  stored a t  -80 "C. Eluted  protein 
fractions were approximately 20 and 40% rGR-DBD and rAR-DBD, 
respectively, as assessed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis Coomassie Blue staining  and Western  blotting. 
RESULTS 
Structure  and Nucleotide  Sequence of 20-kDa Protein 
Gene-Two genomic  clones of the 20-kDa protein gene were 
selected, clone  R6  from  the EcoRI partially digested  library, 
and clone H8 from  the  HaeIII  partially digested library  (also 
cloned  in Charon 4A at EcoRI site with  EcoRI linker).  When 
these genomic fragments were restricted with EcoRI, clone 
R6 yielded 7 bands and clone H8 11 bands on agarose gel 
electrophoresis. 
In  Southern  blot analysis,  two fragments of clone R6 (2,564 
and 1,423  bp,  respectively)  hybridized to  the 5' portion of 20- 
kDa  protein  cDNA  (EcoRI  fragment, nucleotides 237-352 in 
Ref. 22). The 3' portion of the 20-kDa protein cDNA  (nucle- 
otides 353-809) hybridized with two fragments of clone H8 
(1,255 bp  and  approximately 4 kilobases, respectively) (data 
not  shown). Clone H8 also contained a 258-bp EcoRI fragment 
that did  not hybridize with  the cDNA probe. It was demon- 
strated by PCR that this fragment is in the second exon- 
intron region of 20-kDa gene (see Fig. lA). The sequencing 
strategy  and nucleotide  sequence are shown in Fig. 1, A and 
B. Primer  extension  analysis (Fig. 2) together with the cDNA 
sequence reported  earlier  (22,23) indicated that  this genomic 
DNA sequence contains the entire 20-kDa gene sequence 
including 901 bp 5' of the transcription start site with a 
TATA box a t  -22, a 293-bp first exon, 2,709-bp first  intron, 
96-bp second exon, 762-bp second intron, 114-bp third  exon, 
838-bp  third  intron, 325-bp fourth exon, and 267-bp nontran- 
scribed 3' region. 
Androgen Response Element Activities of the  5'-Fhnking 
Region and Intron 1 Fragments-Androgen-dependent en- 
hancer  activities of the 20-kDa protein gene 5'-flanking region 
and  intron 1 fragment were compared in CV1 cells. The 5'- 
flanking  and  intron 1 fragments were cloned into  pCAT  and 
ptkCAT, respectively, both at the  BamHI  site,  and  cotrans- 
fected with  the  rat  androgen receptor  expression,  pCMVrAR, 
in  the  presence  or  absence of the  synthetic  androgen R1881 
(50 nM). No  increase  in  CAT  activity was detected with the 
5' fragment, nucleotides -901 to +8 (created by MboII cleav- 
age) in pCAT (data not shown). When a fragment of this 
region, FL-1  (nucleotides -895 to -38) without  the  putative 
TATA box,  was tested  in  ptkCAT,  CAT  activity was stimu- 
lated only about 2-fold by R1881  (50 nM) (Fig. 3). A  subfrag- 
ment of FL-1, nucleotides -503 to -181, was  also tested  in 
ptkCAT, and CAT activity was stimulated only 2-fold by 
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pendent enhancer activities of In-lc sequences D l ,  D2, and 
N39 in CV1 cells. The diagram at the top shows the fragment In- 
IC and its subfragments Dl, D2, and N39. The restriction enzyme 
site (DdeI) used to generate Dl and D2 is indicated. Symbols in boxes 
indicate relative positions of ARE/GREs and other transcription 
factor recognition  sequences. (V, AP1; &, CREB; #, AP2; *, C/EBP; 
a, OCT-1; also see Tables I and 11). The reporter  vector  pDZtkCAT, 
pDltkCAT, or  pN39tkCAT (5 pg each) was cotransfected with 
expression  vector  pCMVrAR (lanes I and 2 )  or pCMVrGR (lanes 3 
and 4 )  (1 pg each). CAT activity  assays for each  fragment  are  shown 
on the left. Lanes 1 and 2 are in the absence  and  presence of R1881 
(10 nM) respectively; lanes 3 and 4, in the absence  and  presence of 
dexamethasone (10 nM). On the right are  nucleotide sequences D2, 
Dl, and N39. ARE/GRE right half-sites are boxed. The consensus 
GRE sequence is GGTACAn3TGTTCT (40). Transcription factor 
recognition sites are double-underlined (see also Tables I and I1 for 
ARE/GREs and transcription factor recognition sequences). Solid 
ouerline arrows indicate  inverted  repeat  sequences; broken underline 
arrows indicate  direct repeat sequences. 
TABLE I 
Potential regulatory sequences within  intron 1 fragment In-lc: 
Nucleotide sequence ofpotential AREIGREs 
The  15-bp partial palindromes  consist of 6-bp  right  and  left  halves 
separated by a 3-bp  spacer. Right half-sites are  underlined. The In- 
IC sequence  is  underlined in Fig 1. 
Sequence Position" Seauence Position" 
AGCAGATCATGTACT 2684-2698 CACCTTGGGTGTCCT 2787-2801 
ACTGGCAATGGTTCT 2696-2710 TGGGTGTCCTGTTCC 2792-2806 
GTTCTTACCTGTCCT 2706-2720 TAATAAAGATGTACA 2814-2828 
TTACAGGCTGGTTCT 2732-2746 
a All sequences are  located  in  subfragment Dl (see Fig. 6). 
R1881 (data  not  shown). However, with  the  intron 1fragment, 
In-1 (nucleotides 521-2907) CAT  activity  was  stimulated 4- 
8-fold (Fig. 3), indicating that  the  first  intron  fragment  con- 
tains a potential ARE. 
TABLE I1 
Nucleotide sequence ofpotential response elements within  intron 1 
fragment In-lc for other  transcription factors 
Consensus sequences of transcription factors are from Refs. 54 and 
55. 
and  transcription Sequence 
Subfragment 
factor 
Position Homology with 
consensus 
76 
AP1 TGATAAA 2570-2576 71 
CREB TGACTTCT 2655-2662 75 
AP2 CCCAAGGT 2794-2787 75 
D2 
Dl 
C/EBP TGTACAAAG 2823-2831 78 
OCT-1 CTGAAAAT 2841-2848 75 
GACTTTTA' 
C/EBP TGTTGGAAG 2854-2862  78 
a OCT-1  consensus  sequence  reads 5' to 3' on lower strand. 
The  intron 1 fragment, In-1, was cleaved with  the  restric- 
tion enzyme HincII  to yield two fragments which were di- 
gested with AluI. Three  fragments  containing sequences re- 
sembling  GREs were selected, and  their  androgen-dependent 
enhancer activities were tested (Fig. 4). Fragments In-la, 
nucleotides 1420-1779, and In-lb, nucleotides 2013-2290, 
yielded low levels of activity (2-fold or less). However, the 
fragment In-lc, nucleotides 2549-2907, resulted in a 9-fold 
stimulation of CAT activity in initial experiments (Fig. 4). 
For this reason, further studies were focused on fragment 
In-lc. 
Androgen and Glucocorticoid Response Element Activities of 
Intron 1 Fragment, In-1, and Subfragment, In-lc, in CVl 
Cells-The ability of the intron 1 fragment, In-1, and its 
subfragment,  In-lc,  to  enhance  GR  as well as AR transacti- 
vation was tested by cotransfection  analysis in CV1 cells (Fig. 
5). With the large intron 1 fragment, In-1, CAT activity 
increased  with AR and R1881 in  concentrations  up  to lo-' M 
(Fig. 5). However, there was no  increase in  CAT  activity  with 
GR and dexamethasone up to M. With In-lc there was 
strong androgen-stimulated CAT activity but again no re- 
sponse  to  GR  and  examethasone even at  M (Fig. 5). 
This  result was in  contrast  to  the  activities of simple  response 
elements which are  capable of directing  transactivation with 
all  members of the  androgen, glucocorticoid, and progesterone 
subfamily of nuclear  receptors (3,6-11). The sequence specific 
to AR was further investigated by DdeI restriction digestion 
of fragment  In-lc  into two fragments, Dl   and  D2 (Fig. 6). In 
addition, we synthesized a 39-bp oligonucleotide (N39) cor- 
responding to the portion of In-lc containing a cluster of 
three  ARE/GRE-like half-site sequences. Fig. 6 shows that 
the two In-lc  subfragments, D l  and D2, retained androgen 
receptor specificity in  the  CAT  assay (lunes 1 and 2) and did 
not  mediate  GR  transactivation (lanes 3 and 4 ) .  In  contrast, 
N39 containing  three  GRE-like sequences mediated increases 
in CAT activity in response to both R1881-AR and dexa- 
methasone-GR (Fig. 6). The larger fragment (Dl)  contains 11 
ARE/GRE-like sequences including the cluster of three in 
N39 (Fig. 6 and  Tables I and 11) and  potential  transcription 
factor recognition sites for  AP2, C/EBP,  and OCT-1.  Respon- 
siveness of N39 to both AR and GR indicates that other 
factors  interacting  with sequences outside  the 39-bp region 
determine androgen receptor specificity in CV1 cells. The 
smaller  fragment  (D2)  contains  potential  transcription  factor 
recognition sites for AP1  and  CREB  but lacks  a strong  can- 
didate  ARE/GRE. 
We considered the possibility of a suppressor sequence for 
GR  or negative GRE in In-lc  and  tested  this by insertion of 
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TABLE I11 
Effect  of cell type on response element  specificity of In-lc and  its  subfragments D l  and 0 2  
CV1, PC3, and HeLa cells were maintained as described under “Materials and Methods” except that cells were plated in 6-cm culture 
dishes at  4 X lo5 cells/dish. Cells were cotransfected with either the androgen or glucocorticoid receptor expression vector pCMVrAR or 
pCMVrGR (1  pg) together with the reporter vector pIn-lc-tkCAT, pDltkCAT, or pD2tkCAT (5 pg) and incubated in the absence or presence 
of either R1881 or dexamethasone (10 nM). CAT assays were performed as described under “Materials and Methods.” Numbers  represent 
fold stimulation and are the means f standard errors  of five assays. 
cv1 PC3 HeLa 
AR GR AR GR AR GR 
In-lc 19.8 f 1.7 0.7 k 0.1 10.5 k 2.1 2.9 f 0.8 10.7 f 1.7 2.0 f 0.5 
D l  3.9 2 0.7 0.5 f 0.1 3.8 f0.9 1.9 f 0.5 2.4 k 0.6 1.1 f 0.1 
D2 15.4 f 2.5 0.5 f 0.1 7.5 k 0.1 0.7 f 0.1 3.8 f 0.5 0.6 k 0.1 
1 2 3 4 5 6 7  
FIG. 7. Androgen receptor binding to In-lc. Each binding 
reaction contained ‘*P end-labeled In-lc (10,000 cpm) and 1 pg of 
poly(d1-dC). Recombinant rAR-DBD partially purified from Esche- 
richia coli was  incubated with labeled  probe  in the presence or absence 
of unlabeled In-lc and loaded onto  a  4% nondenaturing polyacryl- 
amide gel. Lane I, free labeled probe; lanes 2-7, 1.0 pg of rAR-DBD; 
lanes 3-7, 0.28 pg of antibody AR-52; lanes 4 and 5 each contained 
the indicated molar excesses of unlabeled In-lc; lanes 6 and 7 con- 
tained molar excesses of unlabeled non-specific DNA (N.S .   DNA).  
a 15-bp  partial  palindrome  that  functions  as a strong  ARE  or 
GRE (oligo(C) in  the  C3 gene, Ref. 10).  When  the  ARE/GRE 
was inserted  into  pIn-lctkCAT 5’ of In-lc  and  cotransfected 
into CV1 cells with either AR or GR expression vectors, 
responses to dexamethasone and androgen were similar to 
those observed with oligo(C) alone,  indicating that  In-lc  did 
not  suppress  the  GRE  activity of this  ARE  (data  not  shown). 
However, the  strong  ARE  activity of oligo(C)  may have over- 
come a suppressor of weaker hormone response elements. 
Influence of Cell Type  on  Intron Response Element Specific- 
ity-Possible effects of cell specific factors  on  androgen recep- 
tor specificity of In-lc  and  its  subfragments Dl   and  D2 were 
investigated by transient cotransfection again in CV1 cells 
and  in two additional cell lines, PC3, a human  prostate  cancer 
cell line,  and  HeLa cells. None of these cell lines  contained 
detectable levels of AR. CV1 and PC3 cells also lack GR, 
however, HeLa cells contain  sufficient endogenous GR  such 
that  ransfected mouse mammary  tumor  virus-CAT  re- 
sponded to dexamethasone  without  cotransfection of a GR 
expression vector (33). Fragment In-lc (pIn-lctkCAT) was 
not as selective for androgen in PC3 and HeLa cells and 
mediated responses to both AR and GR; however, RH81 
stimulated a greater  increase in CAT  activity  than did  dexa- 
methasone in both cell lines (Table 111). The response of 
subfragment D l  (pDltkCAT)  to R1881-AR was less than  that 
of In-lc  in all three cell lines. D l  was only  slightly  responsive 
to dexamethasone-GR  in  PC3 cells and  unresponsive in CV1 
and  HeLa cells. On  the  other  hand,  the  smaller  subfragment, 
D2  (pD2tkCAT)  retained  its selectivity  for androgen receptor 
in  all  three cell types, CV1, PC3  and  HeLa cells. Dexameth- 
asone-GR did not  increase  CAT activity with D2 in  any of 
these cell lines  and  the response to R1881-AR was greater 
than  with  Dl. 
Androgen  (AR) and Glucocorticoid (GR) Receptor Binding to 
Intron 1 Fragment, In-lc, and Its Subfragments, D l  AND 
D2-Binding of purified  recombinant AR DNA binding do- 
main polypeptide (rAR-DBD)  to  fragment  In-lc was exam- 
ined  using  the mobility shift DNA binding assay. When rAR- 
DBD was incubated with 32P end-labeled In-lc (Fig. 7), a 
protein-DNA complex  was detected which was shifted  farther 
with  anti-AR  antibody (AR-52)  confirming the  binding of AR 
to  this  fragment. AR binding  to labeled In-lc could be inhib- 
ited  with  unlabeled  In-lc  up  to 1,000-fold molar  excess (lanes 
4 and 5 ) .  Nonspecific  DNA  was  a  less effective competitor of 
AR binding  to  In-lc (lanes 6 and 7). Recombinant  GR DNA 
binding  domain polypeptide (rGR-DBD)  shifted radiolabeled 
In-lc  as did rAR-DBD (Fig. 8A, lanes l a ) ,  and  the  anti-GR 
antibody  (BuGR)  caused a farther  shift  confirming  the  bind- 
ing of GR  to  this  element. Excess  unlabeled In-lc also inhib- 
ited  binding of rGR-DBD  to labeled In-lc  (data  not  shown). 
These results demonstrated that fragment In-lc contains 
recognition  sequences  for AR and GR. However, by compar- 
ison with  the  strong  binding  to  the C3 gene first  intron  ARE/ 
GRE, C3-C  (10) binding of AR and  GR  to  In-lc was  weaker 
(Fig. 8B, lanes 11-14). We  also compared  rAR-DBD and  rGR- 
DBD  binding  to  the Dl   and  D2  subfragments of In-lc  and 
the N39  sequence  located at   the 5’ end of D l  (Fig. 8, A and 
B).   Dl ,  D2, and N39 all  bound  both AR and  GR  as  indicated 
by the  shifted complexes in  the presence of receptor  antibody. 
However, using  amounts of protein  and  antibody  that yielded 
similar AR and  GR  binding  to C3-C, binding of GR  to  In-lc 
and  its  subfragments was  less than  that of AR, especially  with 
D2 and N39 (Fig. 8, A and B ) .  
DISCUSSION 
The 20-kDa protein gene was cloned from a rat genomic 
DNA  library  and  found by sequence analysis  to  contain four 
exons, a large intron 1 and smaller introns 2 and 3. Within 
intron 1 is a region containing multiple partial palindromic 
GRE-like sequences, suggesting that  it  might  function  as a 
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FIG. 8. Androgen  and glucocorticoid receptor  binding  to  In- 
IC and its sequences D l ,  D2,  and N39. Each binding reaction 
contained  32P-labeled  probe (10,000 cpm)  and 0.5 pg of poly(d1-dC) 
in a 20-pl total volume. Recombinant  rAR-DBD or  rGR-DBD  par- 
tially purified from E. coli was incubated with labeled probe and 
loaded onto 4% (panel A )  or 5% (panel B )  nondenaturing polyacryl- 
amide gels. Panel A: lanes 1-5 contained  3ZP-labeled In-lc; lunes 6- 
10 contained  32P-labeled Dl;  lanes I and 6, free labeled probe; lunes 
2,3, 7, and 8, 1.0 pg of total  protein of rAR-DBD; lanes 4, 5, 9, and 
10,2.0 pg of total protein of rGR-DBD; lunes 3 and  8,1.2 pg of protein 
of antibody AR-52; lanes 5 and 10, 2 pl of a 1:5 dilution of BuGR 
antiserum. Panel B lanes 1-5 contained  32P-labeled D2; lanes 6-10 
contained  32P-labeled N39; lanes 11-14 contained  32P-labeled C3-C; 
lanes I and 6, free labeled probe; lanes 2,3, 7,8, 11, and 12, 1.0 pg  of 
total protein of rAR-DBD; lunes 4,5,9, 10, 13, and 14,2.0 pg of total 
protein of rGR-DBD; lanes 3,8, and 12,1.2 pg of protein of antibody 
AR-52; lanes 5, IO, and 14, 2 pl of a 1:5 dilution of BuGR  antiserum. 
Note that for assays with In-lc  and  its subfragments, rAR-DBD and 
rGR-DBD and  their corresponding  antibodies were used in the  same 
amounts in A and B as  those used for C3-C. 
complex androgen response  element.  Intron 1 fragment  In-lc 
was a stronger androgen-dependent enhancer in CV1 cells 
than two other first intron regions, In-la and In-lb, each 
selected by the presence of GRE-like sequences. GRE-like 
sequences were noted  also  in  the 5"flanking  region; however, 
this region was less responsive than either the large first 
intron  fragment  In-1  or  its  subfragment  In-lc. Low levels of 
androgen-stimulated CAT activity were observed with two 
reporter  constructs  each  containing  fragments of the 5"flank- 
ing region in ptkCAT. However, the  5'-flanking  DNA (-901 
to +8) with its own promoter (cloned in  pCAT) was not  an 
effective androgen-dependent  enhancer of transcription.  We 
observed a similar lack of androgen regulation of the C3 
subunit gene promoter  in CV1 cells (10). 
Several  features of the  first  intron  element  In-lc  are  note- 
worthy.  Although In-lc bound  both AR and  GR  in  the DNA 
mobility shift assay, only AR induced a transcriptional re- 
sponse  in CV1 cells. A cluster of GRE-like sequences, N39, 
consisting of a 15-bp  partial  palindrome  and two right half- 
sites,  when isolated  from In-lc  functioned  as a weak ARE  or 
GRE,  although  it  bound AR better  than GR. Thus  the selec- 
tive ARE activity of In-lc was likely determined by AR 
interactions  with  other nucleotide  sequences or with  one or 
more nonreceptor regulatory proteins  interacting outside the 
GRE-like  cluster.  In CV1  cells, ARE specificity of the  Dl  and 
D2  subfragments of In-lc was retained even though  they also 
bound AR and GR. However, transfection of reporter vectors 
containing  In-lc,  Dl,  or D2 into  PC3  and  HeLa cells revealed 
differences in their transcriptional responses. In PC3 and 
HeLa cells, In-lc  and D2 were less  responsive to AR than in 
CV1 cells. In-lc also mediated a weak response to  GR in these 
cells, whereas D2 remained AR-specific. D l  was a weaker 
ARE  than  In-lc  or  D2  in all three cell lines. It exhibited GRE 
activity only in PC3 cells and at  a lower level than ARE 
activity. The selective AR responsiveness of D2 in the  three 
different cell lines suggests that  it is intrinsically AR-specific 
and  is  consistent with its  stronger  binding of AR than GR. 
However, the AR specificity of In-lc was confined to CV1 
cells. Thus,  the  In-lc  subfragments,  Dl  and D2, combined to 
make  In-lc a stronger  ARE  than  GRE  in  PC3  and  HeLa c lls.
The relatively weak GRE activity of In-lc could result from 
a permissive factor for GR  transactivation which is  not pres- 
ent in CV1 cells (34). The factor might be a specific GR 
coactivator  or  an  inhibitor of a  selective GR suppressor. 
The absence of In-lc GRE activity in CV1 cells and its 
presence  in  HeLa cells are  reminiscent of studies  on a com- 
posite GRE of the proliferin gene that contains an AP1 
recognition  sequence and  responded with  repression or  stim- 
ulation of reporter gene expression depending  on  the relative 
amounts of c-Jun  and  c-Fos  in  the cell (16, 35-39). In CV1 
cells, repression of GR transactivation was linked to the 
predominance of Fos/Jun  dimers, whereas  in the  HeLa cells, 
GR-dependent  enhancement of reporter gene expression was 
related to  the  presence of AP1  as  Jun/Jun homodimers  (16). 
In-lc mimics this  pattern of cellular  response  in that  it  is a 
GRE  in  HeLa cells but  not in CV1 cells. However, subfrag- 
ment D2, which contains  both  AP1  and  CREB recognition 
sites, did not mediate a response to GR in either HeLa or 
CV1 cells,  suggesting that  factors  other  than  or  in  addition  to 
Jun   and  Fos may influence the receptor specificity of this 
complex element. 
AR binding  to  In-lc  and  its  subfragments D l  and D2 was 
weaker than to the 15-bp partial palindrome ARE within 
intron 1 of the  C3  subunit gene (10). Low receptor binding 
activity  is a feature of the complex ARE  controlling  the mouse 
sex-limited protein gene (17) and of complex response ele- 
ments described  for GR (15, 16). GRE-like sequences  within 
In-lc,  although  not  tested individually, would be considered 
weak GREs according to  the nucleotide  sequence criteria of 
Nordeen et al. (40). In general, it  has been found  that within 
this family of simple response elements the 15-bp partial 
palindromes  have  both  ARE  and  GRE  activities  (7,14). Based 
on a consensus sequence (10, 14, 40), the strongest simple 
elements of In-lc  are  in  the 39-bp  sequence at  the 5' end of 
the   Dl  subfragment,  and  they  too were relatively weak as  an 
isolated unit when  analyzed in  CAT assays. The absence of 
strong individual  response elements within  a complex element 
may allow for modulation by different factor interactions  (17), 
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thus enabling the element In-lc  to mediate AR-specific trans- 
activation in CV1 cells and yet transact responses to both AR 
and GR in PC3 and HeLa cells. Interestingly, D2 was a 
stronger ARE than  Dl yet  lacks  a sequence conforming to 
that of a consensus ARE/GRE (7, 12, 40). The closest to  an 
ARE/GRE-like 15-bp partial palindrome is GTCA- 
TACTTTGTAAC (nucleotides 2614-2600, 5' to 3' on the 
antisense strand).  It remains to be determined if this is an 
effective AR binding site. 
Winderickx et al. (23) demonstrated that androgen regula- 
tion of 20-kDa protein gene expression requires protein  syn- 
thesis. The testosterone-stimulated  increase in 20-kDa pro- 
tein mRNA was blocked by cycloheximide, indicating that 
rapidly turning over factors might interact with AR and GR 
to control  transactivation. The multiplicity of potential  con- 
trolling  elements  in In-lc provides a structural framework for 
cooperativity among ARE/GRE-like sequences as well as 
interactions with transcription control sequences (Tables I 
and 11). Functional cooperativity was demonstrated among 
GREs and recognition sequences for several transcription- 
regulating proteins including NF1, SP1, CCAAT box, OTF, 
and CACCC box-binding proteins (41-43). NF1 appears to 
have no direct interaction with G R  however, the function of 
OCT-1, another  transcription factor that activates the mouse 
mammary tumor virus promoter, requires direct  interaction 
with the receptor (44). In-lc contains an OCT-1 sequence as 
well as potential recognition sequences for the known factors 
C/EBP, AP1, CREB, and AP2. C B B P  elements are located 
within a glucocorticoid regulatory unit of the  rat  a-acid gly- 
coprotein gene (21). AP1 sites belong to  an overlapping set of 
response elements for Jun/Fos, CREB, and might also me- 
diate effects of cyclic AMP. Rat ventral prostate  contains a 
high density of 8-adrenergic receptors, and adrenergic stimu- 
lation of adenylate cyclase and prostatic binding protein gene 
expression has been demonstrated (45, 46). In  the glutamine 
synthetase gene, glucocorticoid induction of transcription re- 
quired coordination of a  GRE  with an  APl/ATF-CRE-like 
element (47). 
Within In-lc there are a number of inverted and direct 
repeats that may not only serve as recognition sites for cell- 
specific factors but also provide a secondary structure  that 
influences receptor interactions with other  transcription con- 
trol proteins. It is not uncommon for inverted and direct 
repeats to be associated with hormone response elements or 
other transcription  control  elements (10, 19, 48). In  the D2 
subfragment of In-lc, for example, a 7-nucleotide AT-rich 
inverted  repeat (Fig. 6) encompasses the only candidate ARE 
in this subfragment. Similarly in D l  there is a  GC-rich 10- 
nucleotide inverted repeat that could, by looping out,  bring 
several weak ARES into closer proximity. D l  also contains  an 
interesting alternating purine-pyrimidine sequence with 
flanking dyad symmetry (Fig. 6). 
The presence of both AR and GR in rat  ventral  prostate 
epithelial cells provides a capability for overlapping effects of 
androgen- and glucocorticoid-induced gene regulation. Glu- 
cocorticoids in ventral prostate cells act through GR since 
their binding to AR is negligible (49). Both glucocorticoids 
and androgens stimulate prostatein secretion and plasmino- 
gen activator  activity in  short  term cultures of ventral  prostate 
(50-51). However, treatment of castrate  rats with hydrocor- 
tisone only partially replaces the effects of androgen in  pre- 
venting prostate weight loss and  the decrease in  prostatein 
C1  subunit mRNA as well as increases  in plasminogen acti- 
vator activity and mRNAs for TRPM-2  and c-fos (52). GR 
may have an  important role in modulating the expression of 
androgen-regulated genes in  prostate  and  other cells in which 
AR and GR coexist. If so, the effect of GR competition with 
AR for a common response element would depend on the 
nature of the element. Simple elements like the first intron 
element of the C3 subunit gene (10) could mediate equivalent 
positive responses to AR and GR. However, with complex 
elements such as  In-lc  and  others (12, 18) which bind GR 
and AR but respond preferentially to AR, GR could inhibit 
AR transactivation. Development and maintenance of pros- 
tate functions in uiuo are androgen-dependent, and  the pros- 
tate gland undergoes involution following androgen with- 
drawal despite continuing secretion of adrenal corticosteroids. 
Thus, in the absence of androgen in uiuo, positive transacti- 
vation functions of GR which are dependent  on the presence 
of androgen-regulated transcription factors would become 
ineffective. Recent  studies have indicated the involvement of 
androgen-induced DNA-binding proteins  in androgen control 
of the mouse kidney @-glucuronidase (19) and  RP2 genes (53). 
Androgen-regulated transcription control  factors  are likely to 
be the subject of intensive investigation in  future years. 
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